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Abstract New daily persistent headache (NDPH) is a
subtype of chronic daily headache (CDH) that starts
acutely and continues as a daily headache from the onset.
It is considered as one of the most treatment refractory of
all headache syndromes. The pathophysiology is largely
unknown. Viral infections, extracranial surgery, and
stressful life events are considered as triggers for the onset
of NDPH. A few patients may have the onset of their
symptoms during an infection. Here we report nine patients
with NDPH like headache. All of them had a history sug-
gestive of extracranial infections a few weeks prior to the
onset of headache. All patients received intravenous methyl
prednisolone (IV MPS) for 5 days. Intravenous MPS was
followed by Oral steroids for 2–3 weeks in six patients.
The relief of headache started between the second and fifth
days of infusion in all patients. The steady improvement in
headache continued and seven patients experienced almost
complete improvement within 2 weeks. Two other patients
showed complete improvement between 6 and 8 weeks
after initiation of IV MPS therapy. We conclude that
NDPH-like headache may occur as a post infectious
process following a recent infection. We also speculate on
the possible mechanisms of headache in our patients.
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Introduction
New daily persistent headache (NDPH) is a type of chronic
daily headache (CDH). The term NDPH was first coined by
Vansat in 1986 [1]. It falls into group 4 of the International
Headache Society (IHS) classification system. It is char-
acterized as ‘‘daily and unremitting from very soon after
onset (within 3 days at most)’’. The pain is typically
bilateral, pressing or tightening in quality and of mild-to-
moderate intensity. There is considerable overlap in pain
characteristics of NDPH and chronic tension type headache
(CTTH) in the diagnostic criteria [2]. Abrupt onset of a
primary CDH of long duration is the most important fea-
ture for the diagnosis of NDPH. The pathophysiology of
NDPH is largely unknown. Viral infections, extracranial
surgery, stressful life events, etc. are considered as the
triggering factors for the onset of NDPH [3]. The prognosis
and treatment of patients with NDPH are highly variable.
Primary NDPH may be a self-limiting type of headache
that resolves without therapy within several months.
However, recent observations suggest that primary NDPH
may be the most treatment refractory of all primary
headache disorders [4]. Here, we report nine patients with
abrupt onset of daily headache of variable duration. All
patients had history suggestive of infection prior to the
onset of headache and responded to intravenous (IV)
methyl prednisolone (MPS).
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Materials and methods
Case 1 prompted us to look for similar case, and we
observed nine similar patients over a period of about
1.5 years in whom a preceding infection was noted a few
weeks prior to the onset of daily headache. Three patients
are described in detail. The main characteristics features
of other cases are summarized in Table 1. Written
informed consent was taken from the patients to publish
this report.
Case 1
A 36-year-old female presented to our outpatient neurol-
ogy clinic with a complain of daily continuous headache
of about 10-week duration. The headache was present
Table 1 Main features of patients 4–9
Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Age (year) 24 26 32 25 29 20
Sex M M F M M F
Duration of headache
(weeks)
6 16 20 10 14 10
















Associated symptoms No nau, phot No nau nau, phot No
Preceding illness




4 5 3 2 3 3
Duration of illness 3–4 days 10 days 2 weeks 2–3 days 1 weeks 4–5 days
Any investigations Not done Normal Leucocytosis Not done Not done Not done
Treatment cetr, para antb, ibup antb, para Not any specific Detail not known Metr
Investigations
MRI brain Normal Normal Normal Normal Normal Normal












CSF Normal Not done Not done Normal Not done Normal
Others Normal Normal Normal Normal Normal Normal
Prior treatments




amt, Ibu, para, ibu, nap, ind para, val, amt
Response No Minimal Minimal No Minimal No
Treat. with IV MPS
(1,000 mg daily)
5 days 5 days 5 days 5 days 5 days 5 days
Followed with oral
prednisolone




















Total response com in 2 weeks mar in 1 week,
com in 2 weeks
mar in 2 weeks mar in 1 week mar in 1 week,
com in 2 weeks
com in 2 weeks
Follow up no hd in
3 months









occ. mild hd in







Amt amitryptiline; antb antibiotics; cetr cetrizine; com complete; cont = continuous; d days; dot dothiepine; exacer exacerbations; F female;
Gastroent gastroenteritis; hd headaches; hol holocephalic; ibup ibuprofen; indo indomethacin; M male; mar marked; metr metronidazole; mod
moderate; mths months; nap naproxen; nau nausea; occ occasional; para paracetamol; phon phonophobia; phot photophobia; pred prednisolone;
press pressing; puls pulsatile; top topiramate; val valproic acid; vom vomiting
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from the onset, and was described as pressing, holoce-
phalic, and as mild-to-moderate for most of the time.
However, exacerbations to severe intensity (for a few
minutes to a few hours) were noted on a few occasions.
The patient denied the presence of nausea, vomiting,
photophobia, phonophobia, or any cranial autonomic
features even during the exacerbation phase. There was
no prior history of headache or family history of
headache.
The patient gave history of sore throat, cough, and low
to moderate grade fever (up to 102F) of about 1 week
duration. These symptoms subsided with treatment (azith-
romycin and ibuprofen) 2 weeks prior to the onset of daily
headache. The patient did not feel any type of headache
during that febrile period. Routine hematological and bio-
chemical investigations done at that time were normal
except for the presence of leucocytosis.
Prior treatment with various drugs (including indo-
methacin and a short course of oral prednisolone) provided
little or no improvement on headache. Physical examina-
tion did not reveal any abnormality. Repeat hematological
and biochemical investigations were normal. Magnetic
resonance imaging (MRI) of the brain with and without
gadolinium (done after 10 weeks of the headache) was
reported as normal. Cerebro spinal fluid (CSF) revealed
mild pleocytosis (10 cells- all lymphocytes). All other
routine parameters of CSF were normal. As IV MPS is one
of the treatment options for chronic daily headache, giving
a trial of IV MPS was planned. The patient received a
5 days’ course of IV MPS (after taking an informed written
consent). IV MPS (1,000 mg) was given in 500 ml normal
saline over 3 h. The headache started to subside on the
third day of infusion and the patient felt marked
improvement after 5 days’ course of infusion. IV MPS was
followed by Oral administration of prednisolone (60 mg
daily) with gastric protection (omeperazole). The headache
subsided completely in the next 2 weeks. Oral predniso-
lone was gradually tapered off (25% every alternate day)
after 3 weeks. In further 1-year follow-up, she did not
experience any headache.
Case 2
A 32-year-old female presented with an 8-week history of
continuous headache. The headache was daily and almost
continuous since the beginning. It was described as holo-
cephalic, and pressing type. The headache fluctuated from
mild to severe in intensity. However, it was of moderate
intensity for most of the time. She never felt complete
relief from headache since the beginning. The patient
occasionally felt nausea, photophobia, and phonophobia.
There was no prior history of headache, family history of
headache, or history of trauma to head.
The patient had a history suggestive of upper respiratory
tract infection (URTI) in the form of recurrent sneezing,
nasal discharge, myalgia, and fever. These symptoms were
present for about 4–5 days and subsided with over-the-
counter medications (cetrizine and paracetamol) about 3–
4 weeks prior to the onset of daily headache. The patient
did not remember experiencing any headache at the time of
URTI.
Physical and neurological examination did not reveal
any abnormality. Routine hematological and biochemical
investigations were normal. MRI brain (with and without
gadolinium) was reported as normal (done after 8 weeks of
onset of headache). CSF examination revealed mild pleo-
cytosis (14 cells- all lymphocytes). Prior treatment with
various drugs (naproxen, ibuprofen, amitriptyline) had not
produced any significant response on the headache. We
gave a trial of indomethacin, sodium valproate, and short
course of prednisolone. There was just minimal improve-
ment with these drugs. Later on, we gave a trial of IV MPS
(1,000 mg daily for 5 days). The patient responded posi-
tively, and the headache started to improve within 48 h
after the first infusion of IV MPS and it subsided com-
pletely after the fifth infusion of IV MPS. Intravenous MPS
was not followed by any oral drug. However, headache
recurred in mild form after a few days. Oral methyl
prednisolone (48 mg daily) was started and the headache
subsided within 3 days. Oral methyl prednisolone was
withdrawn after 2 weeks. In further 5-month follow-up, she
did not feel any type of headache. Repeat CSF done after
4 weeks returned to normal level.
Case 3
A 33-year old woman presented with about 5-month
history of holocephalic, non-pulsatile, continuous, mild-
to-moderate headache with occasional exacerbations. The
headache was almost continuous since the beginning and
never had period of remission. The exacerbations, in bouts
of a few minutes to a few hours, had a frequency of about
one to two attacks per week. The exacerbations were
occasionally associated with nausea, photophobia, and
phonophobia. However, the feature related to cranial
autonomic involvement was not noted. There was no prior
history of headache, family history of headache or history
of trauma to head. On direct questioning, the patient
admitted to having sneezing, nasal discharge, cough, fever,
and myalgia a few weeks prior to the onset of headache.
These symptoms were treated with over-the-counter med-
ications and the patient was not investigated for that. There
was no other significant past medical history. Physical
examination revealed no abnormality. Routine hemato-
logical and biochemical investigations were normal. CT
brain (at 4 weeks), MRI brain without gadolinium (at
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5 months), and CSF examination (done in early part of the
headache) were reported normal. Prior treatment with
various drugs (paracetamol, naproxen, ibuprofen, dothie-
pin, sodium valproate topiramate, prednisolone, etc.) had
produced minimal effect on the headache.
The patient received a trial of IV MPS (1,000 mg daily
for 5 days), followed by oral methyl prednisolone (16 mg
tds) with gastric protection. The patient started to feel
improvement after fifth infusion of IV MPS. This
improvement continued and there was almost complete
improvement after 2 weeks. After this, oral methyl pred-
nisolone was gradually withdrawn. However, the headache
recurred in continuous pattern with occasional exacerba-
tions. Oral methyl prednisolone was restarted at the dose of
16 mg tds. The headache again subsided completely within
1 week. However, the steroid was withdrawn because of
the beginning of gastritis after 3 weeks. The headache
again reappeared. However, this time headache was very
mild. No treatment was started on this occasion. The
headache subsided completely in the next 2 months.
Discussion
All of our cases fulfilled all the features of IHS criteria for
NDPH, except one stating that the headache should be of
[3 months’ duration in a few patients (case 1, 2, 4, 7, 9) at
the time of first consultation in our outpatient clinic. If we
consider the time required for the complete improvement
(in follow up), all cases except case 4 fulfilled the time
defined in the diagnostic criteria for NDPH. Although
[3 months’ duration is a must in the diagnostic criteria,
daily and unremitting headache from or almost from the
moment of onset is considered the most characteristic of
NDPH. All our patients had acute onset of headache and the
headache was continuous since the beginning. None of
these patients was suffering from medication overuse
headache. The incidence of medication overuse is probably
less in patients with NDPH. The medication overuse was
significantly lower with NDPH than that observed with
other type of CDH in Kung et al.’s study [5]. NDPH-like
headache may be a presentation of another primary head-
ache disorder such as migraine, tension headache, or benign
thunderclap headache. However, a diagnosis of migraine,
tension headache, or other primary headache disorder pre-
senting as NDPH is very difficult to make in the absence of
past history of that primary headache disorders. None of our
patients had past history of any type of primary headache.
Relation of headache with infection
Headache can be an accompaniment to both intracranial
and systemic infection. When the causative (intracranial)
infection is effectively treated, or remits spontaneously, but
headache persists for more than 3 months, then chronic
post infectious headache is diagnosed. The only subgroup
of chronic post infectious headache is chronic post-bacte-
rial meningitis headache. In this group, the headache is a
direct continuation of headache attributed to bacterial
meningitis. There is little evidence for persistent headache
following other intracranial or systemic infections. How-
ever, IHS acknowledged a possibility of post-non-bacterial
infection headache in the Appendix (A9.4.2) [2].
An association of NDPH with infection is widely
reported in the literature. About 30–43% of NDPH patients
may have their headache onset after an infection, and
infectious etiology has been suggested in a subset of
patients with NDPH [3, 6]. Santoni-Santoni-william iden-
tified evidence of extracranial or systemic infections in 108
patients. All patients responded to antibiotics (as inclusion
criteria). Headache was a solitary symptom in about 36%
patients [7]. The serological tests for various viruses have
been done in patients with NDPH. Evidence of Epstein-
Barr virus (EBV) infection (active or past infection) has
been demonstrated in various observations. Diaz Mitoma
et al. [8] demonstrated evidence of active EBV infection in
27 of 32 patients with NDPH compared with 8 of 32
controls. Mack [6] identified 40 patients with NDPH.
Seventeen patients had the onset of headache during an
infection. Of these patients, over half had positive EBV
serology at the onset of symptoms. EBV antibody titers
indicating past infection were identified in 71% of seven
patients tested in Li-Rozen et al.’s case series of 56 patients
[3]. However, later on various other viral infections such as
HSV, CMV, etc. were noted in patients with NDPH [9].
Based on these observations, viral infections have been
implicated as a possible cause for NDPH. However, a
possibility of EBV reactivation secondary to stress result-
ing from chronic headache has also been suggested for
positive EBV titer in patients with NDPH [8].
The relation of headache in post infectious illness has
not been elaborated well in the literature. Various post
infectious CNS disorders may have headache as one of the
accompanying symptoms. However, headache as an iso-
lated or a presenting complain of post infectious illness has
not been well acknowledged in the literature. The classical
post infectious central nervous system disorders are acute
disseminated encephalomyelitis (ADEM) and acute trans-
verse myelitis (ATM). IHS recognizes headache as a
symptom of ADEM. According to the ‘notes’ of IHS
classification, headache is not usually a presenting or
dominant symptom [2]. However, review of the literature
suggests that headache may be a presenting symptom (with
other symptoms) or a predominate feature in patients with
ADEM. Headache was reported as one of the presenting
symptoms in about 27–58% in patients with ADEM [10].
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Johnsen et al. [11] reported four cases of subtle ADEM in
children. In two of them, the main or presenting complain
was headache of a few months’ durations. A computed
tomography (CT) scan of the head in both patients was
normal. However, a MRI brain revealed a few hyper
intense white matter lesions.
Are headache and other clinical profiles of NDPH
comparable to ADEM?
As noted earlier, the most characteristic feature of NDPH is
‘‘daily and unremitting from very soon after onset (within
3 days at most)’’. The onset of ADEM is comparable to
NDPH. The onset of ADEM is rapidly progressive and
usually develops over hours to maximum deficits within
days (mean, 4.5 days) [12]. The clinical characteristics of
headache in patients with ADEM are not described in detail
in the literature. However, it is presumed to be of mild-to-
moderate intensity (like NDPH) [2]. NDPH and ADEM are
both reported predominantly in children and early adult-
hood. Moreover, headache in ADEM is more predominant
in children than adult [12]. NDPH is a slightly female-
predominant disorder. However, a few case series have
demonstrated male predominance or equal male–female
ratio [13, 14]. The male–female ratio was almost equal in
our case series. The associated symptoms described in
patients with NDPH (such as photophobia, phonophobia,
nausea, vomiting, stiffness, concentration problem, blurred
vision, insomnia, tinnitus, numbness, tingling, vertigo,
focal sensory or motor symptoms, etc.) are well-described
features in patients with ADEM [3]. As noted earlier,
serological marker of EBV (recent or past infection) is the
most common viral marker in NDPH. EBV infection is
considered as a main antecedent infection even in patients
with ADEM [15]. The role of neuroimaging in patients
with NDPH is to rule out secondary causes of headache. In
general, there is a suggestion for CT brain for acute
headache and MRI brain for chronic headache disorders
(especially when associated with red flag signs) [16].
NDPH is a chronic headache disorder with acute onset.
Therefore, the type of neuroimaging and timing to perform
it may be vital in patients with NDPH. There is no sug-
gestion or recommendation for neuroimaging in patients
with NDPH. Many case series did not mention any detail
about neuroimaging. In a few case series, neuroimaging
was not done in all the patients [3, 13]. The case series that
reported neuroimaging in their patients did not give details
of neuroimaging, especially the timing when neuroimaging
was performed (and including type of neuroimaging and
use of gadolinium). In our all patients (except case 4) MRI
brain was done only after 8 weeks of onset of headache. It
was reported as normal in all the cases. CSF examinations
were done in a very few case reports/series in the literature,
and it was reported as normal. CSF examinations were
done in our six patients (between 6 and 9 weeks of onset of
the symptoms). Two of them showed mild pleoctyosis with
normal opening pressure, protein and glucose. Repeat CSF
examination was done in one of these patients that returned
to normal in 4 weeks durations. This CSF abnormality is
comparable to CSF abnormality of ADEM. Rozen and
Swidan have demonstrated elevation of tumor necrosis
factor-a (TNF-a) in patients with NDPH [17]. Similar
observation has been observed in patients with ADEM
[12].
The natural course of ADEM cannot be compared with
that of NDPH as course of untreated ADEM is largely
unknown [12]. Treatment with high dose steroid is not
reported in the patients with NDPH in the literature.
However, steroids (including IV MPS) are known as
effective therapeutic agents for treating various types of
chronic or sustained headaches such as status migrainous,
chronic migraine, medication overuse headache, hemicra-
nia continua, etc. [18, 19]. This prompted us to use IV MPS
in case 1. The positive response encouraged to use this drug
in other similar type of patients. Before initiating IV MPS
therapy, we attempted to rule out the possibility of active
infections of the brain and other parts of the body by
careful history taking and investigations. There was a
temporal relation in the beginning of relief in the headache
and administration of IV MPS. The relief of headache
started between the second and fifth day of infusion in all
the patients. The steady improvement in headache contin-
ued and seven patients felt almost-complete improvement
within 2 weeks. In other two patients (cases 6 and 7),
complete improvement was noted between 6 and 8 weeks
after initiation of IV MPS therapy. Six patients received
oral steroids (either prednisolone or methyl prednisolone)
for 2–3 weeks. Withdrawal of oral steroid led to recurrence
of the headache on two occasions in one patient (case 3).
The improvement pattern of headache in our patients was
comparable to that of ADEM.
Are these secondary headaches?
The diagnostic criteria for secondary headaches in the IHS
classification include (A). Headache with one (or more) of
the following characteristics and fulfilling criteria C and D.
(B) Another disorder known to be able to cause headache
has been demonstrated. (C) Headache occurs in close
temporal relation to the other disorder and/or there is other
evidence of a causal relationship. (D) Headache is greatly
reduced or resolves within 3 months (this may be shorter
for some disorders) after successful treatment or sponta-
neous remission of the causative disorders [2].
For most secondary headaches, the characteristics of the
headache itself are poorly described in the literature.
J Headache Pain (2010) 11:59–66 63
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Therefore, diagnostic criterion A does not contribute much
to establish causation. However, criteria B, C, and D
effectively establish causation [2]. As mentioned earlier,
post infectious illnesses are known to produce headache
(criterion B). Viral infection is a common occurrence in the
general population. Viral infections may occur 4–6 times
per year on average in children. Therefore, the medical
history of presumed viral infection may be positive in
about 33–50% of time in children at any time. Therefore, a
causal relation of any disease entity with viral or other
infections should be considered very cautiously. A latency
period of less than 30 days has been suggested as a pos-
sible link between a febrile event and a post infectious
entity [20]. Our cases all have less than 30 days of latency.
Therefore, a possibility of causal link exists in our patients.
As far as criterion D is concerned, seven patients showed
almost complete relief from headache within 2–3 weeks of
initiation of IV MPS therapy. Other two patients showed
marked improvement in 2–3 weeks and improvement
continued for next few months. One patient (case 2)
showed recurrence of headache after completion of 5 days’
course of IV MPS. This patient responded again to oral
steroid. Withdrawal of oral steroid resulted in recurrence of
the headache on two occasions in case 3. This temporal
relation of initiation of steroid therapy and relief from the
headache suggests that IV MPS was pivotal in relief of the
symptoms. However, we cannot rule out other possibilities
for the remission phase—especially spontaneous remission.
A self-limiting form of NDPH is well described in the
literature. There is no data or clinical features that may
predict which patient is going to have self-limiting form of
NDPH. Even the self-limiting form may take up to
24 months to show spontaneous remission [1]. Therefore,
we should be very cautious in claiming any drug as being
efficacious or inefficacious in patients with NDPH, espe-
cially in case reports/series. In the absence of any structural
abnormality in neuro-imaging in our patients, it is difficult
to speculate on that our patients have restricted form of
ADEM. However, the similarity in the epidemiological
features, clinical pattern of headache, associated clinical
features (such as photophobia, phonophobia, nausea,
vomiting, stiffness, concentration problem, etc.) in the lit-
erature, and our patients indirectly points that a subset of
patients with NDPH may have a restricted form of ADEM,
manifesting as an isolated headache. High incidence of
evidence of EBV infection in both disorders further
strengthens this view. Elevation of TNF-a in Rozen and
Swidan case series and mild pleocytosis in our two cases in
CSF are other supporting points for this notion. History of
antecedent infections and a temporal relation of relief with
high-dose intravenous steroid in our patients are two new
observations that further reinforce the possibility of head-
ache of post infectious origin. The response to IV MPS was
early and marked in the patients with history of shorter
duration (less than 4 months). This indicates that early
initiation of the therapy may be vital in providing remission
phase.
Mechanisms
Our cases and review of the literature suggest that head-
ache of NDPH is comparable to that of ADEM. Therefore,
headache in our patients and a subset of patients of NDPH
may be a part of paucisymptomatic encephalomyelitis. It is
difficult to speculate on the possible mechanisms of
headache in our patients as the mechanisms of headache
even in ADEM (and other demyelinating disease) and
NDPH is not well explored in the literature. Acute onset of
headache in patients with NDPH is highly suggestive of
some etiology. It is puzzling for the treating physician not
to find any abnormality in neuroimaging and laboratory
investigations [4]. CNS immune activation is considered as
a possible mechanism for the development of ADEM. The
demonstration of proinflammatory cytokine in CSF in the
Rozen–Swidan study suggests CNS activation in the
patients with NDPH. Di Lorenzo et al. reported a case of
NDPH secondary to heat stroke and suggested a possibility
of immune reaction as a mechanism [21]. In patients with
acute onset of headache, usually CT scan is advised, but
CT scan is not a good diagnostic tool for investigating a
possible demyelinating lesion. MRI brain with double dose
contrast is preferable for a demyelinating lesion. MRI brain
done in late part of the demyelinating disease may not
reveal any abnormality, as lesions tend to resolve with time
[11]. In most of our patients, MRI brain was done after
2 months. MRI brain with double-dose gadolinium in early
part of the disease is required. ADEM is known to involve
meninges, and meningeal features (such as nausea, vom-
iting, photophobia, meningeal signs) are common features
in the patients with ADEM [10–12]. Lymphocytic menin-
gitis has been demonstrated in the patients with ADEM
[10]. Most of our patients had nausea, photophobia, or
phonophobia. Although meningeal sign was absent in our
patients, neck stiffness (with nausea, photophobia, phono-
phobia) was a common accompanying feature (50%) in Li
and Rozen’s case series of NDPH [3]. This indirectly
suggests a possibility of meningeal involvement in a subset
of patients with NDPH, including our cases. The presence
of CSF pleocytosis in our two cases may be an indication
of secondary NDPH.
Besides this, mechanisms responsible for other post
infectious illness (such as reactive arthritis) may be
responsible for the generation of the headache. Reactive
arthritis (ReA) is a non-purulent joint inflammation sec-
ondary to a primary infectious process elsewhere in the
body. The proposed mechanisms for the generation of
64 J Headache Pain (2010) 11:59–66
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ReA is the persistence of pathogenic organisms or its
products in the joint/synovium leading to local immune
response [22]. The course of ReA is comparable to that of
NDPH: short or self-limiting form, continuous, and
remitting form [22]. Although acute ReA may be associ-
ated with low TNF-a, chronic ReA shows high production
of TNF-a (like NDPH) [23]. Therefore, we speculate a
local immune reaction in the meninges for the generation
of headache in our patients and a subset of NDPH. The
response to steroid is another point to suggest immuno-
logical or inflammatory pathophysiology in our patients as
high dose of IV MPS or other steroid is well known ther-
apeutic option in many post infectious illness. NDPH
usually begins with infection (flu like illness). The non-
headache symptoms resolve but headache remains. We can
call it as ‘immediate post infectious NDPH’. However, in
our case series headache appeared only after 2–5 weeks of
febrile illness (delayed post-infectious NDPH). Delayed
onset of headache after a febrile period may be because of
milder immune response, thus more amenable to steroid
therapy.
The very high levels of steroid obtained by MPS prob-
ably act in some different ways. Boumpas [24] suggests
that very high dose steroid increases NF-kappaB binding
protein in the cytosol that may reduce the amount of pro-
inflammatory transcription factors. Buttgereit et al. [25]
have suggested that very high dose of steroid will lead to
activation of membrane-bound steroid receptor and phys-
ico-chemical interactions with cellular membrane to
increase immunosuppression.
Chronic administration of steroids is known to result in a
number of side effects. The first reported use of mega doses
of IV steroid was in 1969 to prevent renal allograft rejec-
tion and this type of therapy was termed as ‘Big Shot’.
Since the beginning of the use of high-dose pulses of
corticosteroid, there was anticipation that there would be
significant and limiting side effects. Although various types
of side effects are reported with IV MPS, it is generally
considered as safe as majorities of the side effects are
transient and self-limiting and do not require specific
treatment. A few case reports of sudden death have been
reported following rapid administration of MPS (adminis-
tered over less than 10 min). Therefore, it should not be
administered rapidly. Ideally, it should be infused slowly
over 2–3 h (not less than 30 min) [26, 27]. Recently,
Hussain et al. [28] reported three patients with chronic
severe migraine who developed aseptic osteonecrosis
(AON) with short-term, intermittent pulse doses of ste-
roids. We should be cautious for this disabling condition in
patients who have received steroids for disabling and
chronic headache, as both chronic severe headache and
steroid use may be risk factors for AON. None of our
patients showed any side effects related to IV MPS. One
patient (case 3) showed mild gastrointestinal symptoms
with oral steroid on follow-up.
Although we observed our patients prospectively, it has
a number of limitations. We did not compare it with other
patients with NDPH. We observed eight more patients with
NDPH (but without history of any antecedent infection)
during the same observation period. Only two patients
received IV MPS and both showed only minimal response
to the therapy. Our all patients admitted to having ante-
cedent infections before the onset of headache. However,
we do not have any serological evidence for that. Another
limitation in our observation is headache of shorter dura-
tion. Our five patients had a history of less than 3 months at
the time of consultation. Duration of headache in other four
patients was between 14 and 20 months. Besides these, we
cannot rule out even the possibility of other cause of
headache (secondary) responsive to steroid, as full evalu-
ation for secondary headache was not done.
If our observations and treatment response of IV MPS
can be confirmed in other cases, it could be a therapeutic
option for the patients with NDPH-like headache with
history of antecedent infections, especially if caught in
early stage. It will also open a window to take a trial of
other immunosuppressive drugs in refractory cases of
NDPH. It is also hoped that these cases may serve as a
catalyst for early investigations (MRI with gadolinium,
CSF examinations, search for biological markers, etc.) to
clarify the issue.
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